The transaction delivers a meaningful premium relative to the Company’s intrinsic value, representing a 24.9% premium to the midpoint of the Company’s discounted cash flow analysis based on management ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Nordisk shares fell nearly 30% in the fourth quarter on disappointing clinical trial data, and other concerns. Bank of ...

After holding leadership positions at contract manufacturers Patheon and Thermo Fisher Scientific, working in the food and ...

Healthcare proved to be a resilient market for mergers and acquisitions in 2024, despite deal volume declining 9% from 2023. ...

The "Semaglutides Market Report 2024" report has been added to ResearchAndMarkets.com's offering. This Semaglutides market report covers market characteristics, size and growth, segmentation, regional ...

DelveInsight, a leading provider of healthcare competitive intelligence, partnered with a large pharmaceutical company seeking to advance their API and FD development and assessed various CDMO ...

A large pharmaceutical company collaborated with DelveInsight to evaluate CDMO companies for API and FD development. DelveInsight provided a comprehensive one-time report benchmarking top contract ...

Shares of Catalent, Inc. (NYSE:CTLT – Get Free Report) have been given an average rating of “Hold” by the seven analysts that are presently covering the company, Marketbeat.com reports. Seven analysts ...

StockNews.com began coverage on shares of Catalent (NYSE:CTLT – Free Report) in a research report sent to investors on Friday ...

S&P MidCap 400 constituent Lennox International Inc. (NYSE: LII) will replace Catalent Inc. (NYSE: CTLT) in the S&P 500, ...